Bioventus Inc logo

BVS - Bioventus Inc Share Price

$11.49 -0.5  -4.0%

Last Trade - 05/03/21

Sector
Healthcare
Size
Mid Cap
Market Cap £461.8m
Enterprise Value £524.2m
Revenue £231.3m
Position in Universe 3213th / 6651
Bullish
Bearish
Unlock BVS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
242.9 253.7 274.5 292.1 319.2 340.1 +7.0%
-81.4 +535.6
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 26 September 2020,Bioventus Inc revenues decreased 8% to $222.6M. Net incomeapplicable to common stockholders excluding extraordinaryitems totaled $3.9M vs. loss of $1.6M. Revenues reflectU.S. segment decrease of 7% to $204M, International segmentdecrease of 24% to $18.5M. Net Income reflects Selling,general ane expe decrease of 12% to $123.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BVS Revenue Unlock BVS Revenue

Net Income

BVS Net Income Unlock BVS Revenue

Normalised EPS

BVS Normalised EPS Unlock BVS Revenue

PE Ratio Range

BVS PE Ratio Range Unlock BVS Revenue

Dividend Yield Range

BVS Dividend Yield Range Unlock BVS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BVS EPS Forecasts Unlock BVS Revenue
Profile Summary

Bioventus Inc is a global medical device company. The Company is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone. The minimally invasive fracture treatment offers its Exogen system for the non-invasive treatment of established nonunion fractures and certain fresh fractures.

Directors
Last Annual December 31st, 2019
Last Interim September 26th, 2020
No. of Shareholders: n/a
No. of Employees: 680
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 55,625,326
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BVS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BVS
Upcoming Events for BVS
Frequently Asked Questions for Bioventus Inc
What is the Bioventus Inc share price?

As of 05/03/21, shares in Bioventus Inc are trading at $11.49, giving the company a market capitalisation of £461.8m. This share price information is delayed by 15 minutes.

How has the Bioventus Inc share price performed this year?

Shares in Bioventus Inc are currently trading at $11.49 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioventus Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Bioventus Inc?

There are no analysts currently covering Bioventus Inc.

When will Bioventus Inc next release its financial results?

Bioventus Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-26
What is the Bioventus Inc dividend yield?

Bioventus Inc does not currently pay a dividend.

Does Bioventus Inc pay a dividend?

Bioventus Inc does not currently pay a dividend.

When does Bioventus Inc next pay dividends?

Bioventus Inc does not currently pay a dividend.

How do I buy Bioventus Inc shares?

To buy shares in Bioventus Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bioventus Inc?

Shares in Bioventus Inc are currently trading at $11.49, giving the company a market capitalisation of £461.8m.

Where are Bioventus Inc shares listed? Where are Bioventus Inc shares listed?

Here are the trading details for Bioventus Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BVS
What kind of share is Bioventus Inc?

Based on an overall assessment of its quality, value and momentum, Bioventus Inc is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bioventus Inc share price forecast 2021?

We were not able to load any forecast data for Bioventus Inc.

How can I tell whether the Bioventus Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioventus Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $11.49, shares in Bioventus Inc are trading at -17.55% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bioventus Inc PE Ratio?

The Bioventus Inc PE ratio based on its reported earnings over the past 12 months is 54.64. The shares are currently trading at $11.49.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bioventus Inc?

We were unable to find the directors for Bioventus Inc.

Who are the major shareholders of Bioventus Inc?

Here are the top five shareholders of Bioventus Inc based on the size of their shareholding:

EW Healthcare Partners Venture Capital
Percentage owned: 32.69% (13.0m shares)
Smith & Nephew Group plc Corporation
Percentage owned: 15.64% (6.23m shares)
Spindletop Healthcare Capital L.P. Individual Investor
Percentage owned: 9.81% (3.91m shares)
Ampersand Capital Partners Private Equity
Percentage owned: 8.17% (3.26m shares)
Pantheon Global Co-Investment Opportunities Fund L.P. Individual Investor
Percentage owned: 7.08% (2.82m shares)
Similar to BVS
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.